Vitiligo Treatment Options Compared: What the Evidence Actually Says (2026)

One of the most disorienting things about vitiligo treatment is that there is no one right answer. Dermatologists recommend different options depending on the location of your patches, how active the vitiligo is, your skin type, your budget, and your access to phototherapy. That makes comparison genuinely hard.

This page puts every major option side by side — not to pick a winner, but to help you understand what each treatment is doing, who it suits best, and what the evidence actually says.

The treatments covered here

Narrowband UVB phototherapy (NbUVB)
Ruxolitinib cream (Opzelura)
Tacrolimus ointment (Protopic)
Topical corticosteroids
Excimer laser
Oral JAK inhibitors (emerging)
Depigmentation (monobenzone / Benoquin)
Supportive care (not a treatment, but affects everything else)

Narrowband UVB phototherapy

How it works: UVB light at 311–313nm stimulates residual melanocytes in and around depigmented patches, triggering them to produce melanin and migrate back into the patch. It also has an immunosuppressive effect on the local skin environment.

Evidence level: Strong. NbUVB has the longest track record of any active vitiligo treatment and remains the most widely recommended option by dermatologists globally.

Best for: Widespread vitiligo, active spreading, or patients who cannot access or afford prescription topicals. Also the best-studied combination partner for topical treatments.

Practical notes: Requires 2–3 sessions per week, consistently, for 6–18 months. Can be done at home with a UVB lamp — more affordable than clinic-based treatment long-term. Facial and truncal patches respond better than acral areas. The home phototherapy guide covers how to do this safely.

Cost: Home lamp: £200–£700 one-time. Clinic: £50–£150 per session.

Limitations: Time-intensive. Hairless acral skin (palms, soles) is resistant. Does not work as fast alone as in combination.

Ruxolitinib cream (Opzelura)

How it works: JAK1/JAK2 inhibitor. Blocks the IFN-γ/JAK-STAT pathway that drives the autoimmune destruction of melanocytes. Reduces immune attack, allowing melanocytes to survive and repopulate.

Evidence level: Strongest of any topical specifically for vitiligo repigmentation. Only FDA-approved topical for nonsegmental vitiligo in patients 12+.

Best for: Facial and sun-exposed vitiligo. Best results in combination with NbUVB. Good first option for patients who have prescription access.

Practical notes: Apply twice daily. Full trial period is 6–12 months before assessing. Works poorly on hands and feet without combination UVB. Application-site acne is common early on.

Cost: $2,000+/month without insurance. With insurance and co-pay assistance, often manageable. Requires step therapy documentation in many insurance plans. See the insurance appeal guide.

Limitations: Insurance access is the main barrier. Expensive out of pocket. Hands and feet respond poorly. Stopping treatment typically leads to gradual re-depigmentation.

Tacrolimus ointment (Protopic 0.1%)

How it works: Calcineurin inhibitor. Blocks T-cell activation in the skin. Different mechanism to ruxolitinib, similar end result — less immune attack on melanocytes.

Evidence level: Moderate. Decades of use in vitiligo but no FDA approval specifically for it (off-label). Multiple smaller studies show benefit, particularly on the face and sensitive areas.

Best for: Facial vitiligo, especially around the eyes, eyelids, and mouth where corticosteroids are too risky long-term. Often the first prescription topical used as step therapy before ruxolitinib.

Practical notes: Burning and stinging common in the first 2–4 weeks. Usually settles. Requires patience — response is slower than ruxolitinib. Works well in combination with NbUVB.

Cost: £40–£120/month (significantly cheaper than ruxolitinib). Often covered by NHS in the UK. In the US, usually available with standard insurance.

Limitations: Slower and less effective than ruxolitinib in head-to-head comparisons, though not directly trialled against each other in a large RCT. Not suitable as the only approach for extensive or active vitiligo.

Topical corticosteroids

How it works: Suppress local inflammation and immune activity. Older mechanism but still useful, particularly for stable, localised patches.

Evidence level: Moderate. Long track record in vitiligo, particularly for short-term stabilisation. Risk of skin atrophy, telangiectasia, and striae with long-term use means dermatologists usually limit treatment duration.

Best for: Short-term stabilisation of active spreading. Useful on the body (trunk, limbs) where the risk of skin thinning is lower than on the face. Often rotated with tacrolimus for longer-term maintenance.

Practical notes: Mid-potency (e.g. clobetasone butyrate) for the face and children. Potent (e.g. betamethasone) for the body. Maximum 3 months continuous use on any area. Do not use on eyelids or in skin folds without dermatologist guidance.

Cost: Low. Usually covered by insurance or NHS.

Limitations: Cannot be used long-term. Skin atrophy risk on thinner skin. Not a repigmentation strategy on its own — more useful for stopping active spread.

Excimer laser (308nm)

How it works: Concentrated, targeted UVB dose (308nm — the same therapeutic wavelength as NbUVB) delivered directly to the vitiligo patch, sparing surrounding pigmented skin from UV exposure.

Evidence level: Good. Particularly effective for localised, well-defined patches that are too small or irregularly shaped for whole-body NbUVB treatment to be efficient.

Best for: Focal or segmental vitiligo, isolated patches on the face or body, areas that need a higher dose than home NbUVB can deliver.

Practical notes: Clinic-based — requires access to a dermatology practice with excimer equipment. Typically 2 sessions per week. Sessions are fast (a few minutes per patch). Good data for facial patches especially.

Cost: £80–£200 per session; usually 20–30+ sessions needed for a full course.

Limitations: Not accessible outside major dermatology centres. Too expensive and impractical for widespread vitiligo. Not suitable as a standalone for extensive disease.

Oral JAK inhibitors (emerging)

How it works: Same mechanism as ruxolitinib cream but systemic — the drug circulates in the bloodstream and reaches every area of skin, including the treatment-resistant acral sites that topical application cannot reach adequately.

Evidence level: Emerging. Upadacitinib (Rinvoq) has the most data in vitiligo — see the Rinvoq for vitiligo guide. Oral ruxolitinib is in Phase 2 trials. Not yet approved for vitiligo in the US or UK.

Best for: Patients with widespread or rapidly spreading vitiligo that has not responded to topical therapies. Acral vitiligo that does not respond to topical ruxolitinib is a candidate indication.

Practical notes: Prescription only. Used off-label for vitiligo currently. Requires monitoring for side effects including infection risk, lipid changes, and (rarely) cardiovascular effects with long-term use. Benefit–risk conversation with a dermatologist is essential.

Cost: High — typically $1,500–$2,500/month without insurance. Access is limited to specialists.

Limitations: No approved indication for vitiligo yet (as of 2026). Safety profile requires monitoring. Long-term use data in vitiligo specifically is limited.

Depigmentation (monobenzone / Benoquin)

How it works: The opposite of repigmentation. Monobenzone (Benoquin) chemically destroys residual melanocytes in pigmented skin, achieving a uniform, depigmented appearance. This is a permanent, irreversible decision.

Evidence level: Effective for what it does. This is not a cure or a recovery treatment — it is an acceptance treatment.

Best for: Extensive vitiligo covering more than 50% of the body surface where repigmentation is unlikely and the contrast between patches and remaining pigmented skin causes significant distress.

Practical notes: Decision should be made slowly and with psychological support. Depigmented skin requires lifetime sun protection. Cannot be reversed. Application takes months and may spread depigmentation beyond intended areas.

Cost: Benoquin cream is expensive (£200+/month). NHS prescriptions are possible in appropriate cases.

Limitations: Permanent. Psychologically significant decision. Not appropriate for localised vitiligo or patients who still have good repigmentation prospects.

Head-to-head comparison

Treatment	Evidence	Best location	Cost	Reversible	Accessible
NbUVB phototherapy	Strong	Face, body, all sites	Low (home)	Yes	Good
Ruxolitinib cream	Strong (approved)	Face, sun-exposed	High	Yes	Insurance-dependent
Tacrolimus ointment	Moderate	Face, sensitive areas	Moderate	Yes	Good
Topical corticosteroids	Moderate	Body (short-term)	Low	Yes	Good
Excimer laser	Good	Focal patches	High (clinic)	Yes	Limited
Oral JAK inhibitors	Emerging	Widespread, acral	High	Yes	Specialist only
Depigmentation	Effective for intent	Extensive disease	Moderate	No	Moderate

How dermatologists typically sequence these

Most evidence-based dermatologists follow a progression rather than picking one treatment:

Stabilise active spreading first — topical corticosteroids or tacrolimus short-term
Add NbUVB — either home-based or clinic-based, 3x weekly
Add ruxolitinib or tacrolimus — topical on active patches while NbUVB continues
Reassess at 6 months — is it working? Which areas? Is the right combination in place?
Escalate for resistant areas — excimer for focal patches, discussion of oral JAK inhibitors for resistant widespread disease

The combination of ruxolitinib cream plus NbUVB is currently the most evidence-backed approach for patients who have prescription access and can commit to the phototherapy schedule.

My take

I spent a lot of time as a patient thinking there was one right treatment I just hadn’t found yet. What I eventually understood is that it is almost always a combination, and almost always requires more patience than you expect. The question to ask your dermatologist is not “which treatment should I use?” but “what is the plan for each area, what combination are we targeting, and what does success look like at 6 months?”